Subcutaneous tanezumab 2.5 MG or 5 MG for patients with osteoarthritis of the knee or hip: onset and maintenance of efficacy over 24 weeks

Authors :: Lars Viktrup
R. Langford
Francis Berenbaum
Takaharu Yamabe
Naoki Isogawa
Serge Perrot
Rod Junor
Mark T. Brown
Francisco J. Blanco
S. Araki
William Carey
Kenneth M. Verburg
K. Miki
Christine R. West
Source :: Osteoarthritis and Cartilage. 28:S144-S145
Publication Year :: 2020
Publisher :: Elsevier BV, 2020.

Subjects :: chemistry.chemical_compound
Rheumatology
chemistry
business.industry
Tanezumab
Anesthesia
Biomedical Engineering
Medicine
Orthopedics and Sports Medicine
Osteoarthritis
business
medicine.disease

Tools